Company Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.
Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
The company’s product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients.
It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC.
Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | James Parslow |
Contact Details
Address: 945 Concord Street Framingham, Massachusetts 01701 United States | |
| Phone | 781 778 7720 |
| Website | xeneticbio.com |
Stock Details
| Ticker Symbol | XBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534525 |
| CUSIP Number | 984015503 |
| ISIN Number | US9840156023 |
| Employer ID | 45-2952962 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James F. Parslow | Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | SCHEDULE 13G | Filing |
| Jan 9, 2026 | 8-K | Current Report |
| Dec 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 11, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Oct 31, 2025 | ARS | Filing |
| Oct 31, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |